4BASEBIO PLC

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

UK adopted International Accounting Standards

Reporting scope

Consolidated group

Auditor

Crowe U.K. LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have, at the time of approving the financial statements, made a thorough assessment of the Group's ability to continue as a going concern for a period of at least 12 months from the date of approval of the financial statements. In assessing the Group's going concern status, the Directors are confident that the Group has sufficient liquidity available to continue in operation for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.”

Group structure

1. 4BASEBIO PLC · parent
   1. 4basebio S.L.U. 100% · Spain · R&D and manufacturing
   2. 4basebio UK Limited 100% · Cambridge, UK · Manufacturing
   3. 4basebio Discovery Limited 100% · Cambridge, UK · R&D & manufacturing

Significant events

• “The Group doubled its revenues from DNA sales against the previous year, with overall revenues of £933k.”
• “4basebio supplied opDNA™ to its client HelixNano Technologies Inc. for the manufacture of an mRNA vaccine product for use in a first in human trial.”
• “The Group commenced supply of HQ and GMP grade synthetic DNA into a tier one pharma company's vaccine programme.”
• “The Group received its GMP manufacturing licence from the UK regulator, the Medicines and Healthcare products Regulatory Agency.”
• “The Group's intellectual property portfolio now comprises 29 patent families.”
• “A £40 million primary equity investment concluded in November 2024.”
• “The Group formed a Strategic Advisory Board during the year.”
• “On 20 March 2025 the Company issued 18,998 shares in relation to an Employee Share Incentive Plan.”
• “On 7 April 2025, 4basebio Inc. was incorporated in the US state of Delaware. It is currently dormant.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

9

last 12 months

Capital events

4

last 24 months

Officers appointed

1

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +84.4%

  £506,000 → £933,000

• Cash

  +1,027.5%

  £3,069,000 → £34,604,000

• Net assets

  +5,461.8%

  -£492,000 → £26,380,000

• Employees

  +29.9%

  77 → 100

• Operating profit

  -49.6%

  -£8,052,000 → -£12,042,000

• Profit before tax

  -51.5%

  -£8,354,000 → -£12,654,000

• Wages

  +36%

  £3,900,000 → £5,303,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers